Nov 19 (Reuters) - ProMetic Life Sciences Inc PLI.TO :
* Enters into strategic agreements with Prothera Biologics to develop
plasma-derived inter-alpha inhibitor proteins ("IAIP") for orphan diseases
* Says Prometic to receive up to 22.5% equity stake in Prothera
* Says Prometic to pursue two orphan indications, including a pediatric orphan
indication
* Says Prometic and prothera each will perform development services in order to
advance IAIP to the clinic by 2017
* Under terms, Prometic and prothera each will perform development services in
order to advance IAIP to the clinic by 2017
* Prometic will exclusively manufacture iaip for clinical trial requirements
and commercial sales for all indications
* Says Prometic has received an initial 11.25 % equity stake in prothera
* Agreements provide co with global,exclusive intellectual property rights to
commercialize products for two clinical indications
* Source text for Eikon ID:nCNWPs6sTa
* Further company coverage PLI.TO